Numerous studies have shown that as a tumor suppressor, BTG2 is inhibited in human cancers, such as skin, lung, breast, and gastric cancers, and in bladder carcinoma 17, 18, 19, 20. This evidence concerns the gene BTG2 and gastric cancer.